We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-13.26%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.83B
AUM Growth
-$2.02B
Cap. Flow
-$868M
Cap. Flow %
-17.97%
Top 10 Hldgs %
38.68%
Holding
126
New
2
Increased
20
Reduced
30
Closed
20

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$61.8M
2
MASI
Masimo
MASI
+$53.3M
3
CCCC icon
C4 Therapeutics
CCCC
+$49.5M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$28.5M
5
TSVT
2seventy bio
TSVT
+$20.9M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$423M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$112M
3
APLS
Apellis Pharmaceuticals
APLS
+$85.6M
4
ITOS
iTeos Therapeutics
ITOS
+$67.7M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$59.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNCE
51
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$21.6M 0.45%
201,967
+3,217
+2% +$504K
VTYX
52
DELISTED
Ventyx Biosciences
VTYX
$21.1M 0.44%
1,551,778
– –
TSVT
53
DELISTED
2seventy bio
TSVT
$21M 0.43%
+1,229,508
New +$20.9M
LUNG icon
54
Pulmonx
LUNG
$87.6M
$19.8M 0.41%
798,255
-366,345
-31% -$9.46M
OLK
55
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$18M 0.37%
1,018,188
– –
GLUE icon
56
Monte Rosa Therapeutics
GLUE
$1.35B
$17M 0.35%
1,214,572
– –
EPIX
57
DELISTED
ESSA Pharma
EPIX
$16.3M 0.34%
2,637,192
– –
ITOS
58
DELISTED
iTeos Therapeutics
ITOS
$15.7M 0.33%
489,014
-1,864,001
-79% -$67.7M
CTMX icon
59
CytomX Therapeutics
CTMX
$754M
$15.4M 0.32%
5,779,700
-250,000
-4% -$960K
NSTG
60
DELISTED
NanoString Technologies, Inc.
NSTG
$14M 0.29%
404,029
-200,000
-33% -$6.89M
BWAY
61
Brainsway
BWAY
$622M
$14M 0.29%
3,204,762
– –
WHWK
62
Whitehawk Therapeutics
WHWK
$271M
$13M 0.27%
764,701
– –
RCOR
63
DELISTED
Renovacor, Inc.
RCOR
$12.7M 0.26%
3,000,803
+353,263
+13% +$2.11M
TELA icon
64
TELA Bio
TELA
$38.9M
$11.8M 0.24%
1,017,546
-382,140
-27% -$4.63M
SGHT icon
65
Sight Sciences
SGHT
$412M
$11.5M 0.24%
997,099
-186,772
-16% -$2.87M
LJPC
66
DELISTED
La Jolla Pharmaceutical Company
LJPC
$9.94M 0.21%
2,327,403
-500
-0% -$2.18K
AGEN
67
Agenus
AGEN
$290M
$8.81M 0.18%
182,527
-116,464
-39% -$6.29M
PYXS icon
68
Pyxis Oncology
PYXS
$236M
$8.57M 0.18%
2,120,760
– –
XGN icon
69
Exagen
XGN
$166M
$7.95M 0.16%
990,143
+168,729
+21% +$1.45M
URGN icon
70
UroGen Pharma
URGN
$2.29B
$7.47M 0.15%
857,464
– –
NYXH
71
Nyxoah
NYXH
$147M
$6.6M 0.14%
344,911
– –
PRQR icon
72
ProQR Therapeutics
PRQR
$265M
$6.35M 0.13%
7,019,610
-8,115
-0.1% -$27.2K
LABP
73
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$6.31M 0.13%
427,572
– –
RACB
74
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$6.22M 0.13%
637,000
– –
BLSA
75
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$6.04M 0.13%
612,500
– –
1 2
3
4 5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q1 2022 Portfolio in Review

As of Q1 2022, RTW Investments held 126 positions worth $4.83B, down 29% from $6.85B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

RTW Investments withdrew a net $868M in Q1 2022, closing 20 positions and reducing 30 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $423M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, RTW Investments opened a new position in CinCor Pharma, Inc. Common Stock worth $24.4M.

  • RTW Investments's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 1,389,705 shares worth $24.4M.
  • RTW Investments added most to Protagonist Therapeutics in Q1 2022, an estimated $61.8M increase.
  • RTW Investments's biggest Q1 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $85.6M.
  • RTW Investments fully exited State Street SPDR S&P 500 ETF Trust in Q1 2022, selling an estimated $423M.
  • RTW Investments's ten largest holdings make up 39% of its $4.83B portfolio in Q1 2022.
  • RTW Investments opened 2 new positions and closed 20 in Q1 2022.
  • RTW Investments's portfolio value fell 29% quarter-over-quarter to $4.83B.

Based on RTW Investments's 13F filing for Q1 2022, filed 16 May 2022.